H.C. Wainwright analyst Raghuram Selvaraju downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of $107, up from $90, after Merck said it will acquire Verona for $107 per American depository share. The firm does not expect any competitors to attempt to outbid Merck.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma downgraded to Neutral from Overweight at Piper Sandler
- Verona Pharma downgraded to Hold from Buy at Truist
- Verona Pharma downgraded to Peer Perform from Outperform at Wolfe Research
- Verona Pharma downgraded to Neutral from Buy at Roth Capital
- Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal